ASMB•benzinga•
Assembly Biosciences Reports Interim Phase 1a Results From Trial Of ABI-1179; Says ABI-1179 Was Well Tolerated With Half-Life Of Approximately Four Days
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga